Trial Profile
Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2016
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors CPEX Pharmaceuticals
- 12 Jul 2010 Planned end date changed from 1 Jan 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 12 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 May 2009 Planned initiation date (Jul 2009) added as reported by ClinicalTrials.gov.